Anyone know if CRISPR technology is much of a threat to Admedus immunotherapy division?
Or is that still a long way off to be practical?
I topped up today. My average is $0.41 so still below - but the revenue growth PCP impressive enough. And I am encouraged by the new sales people coming online.
Medical sales is a tough slog - I work in hospitals - need personnel 'in the face' of each surgeon who uses the product 24/7 (including often standing inside the operating theatres).
Anyone know if CRISPR technology is much of a threat to Admedus...
-
- There are more pages in this discussion • 186 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |